A
Aspire Biopharma Holdings, Inc.
Period
FY 2025
Revenue
—
Net Income
$-24.48M
Total Assets
$1.31M
Equity
$-6.38M
Shares Out
1.30M
Op. Cash Flow
$-4.92M
Business
Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company developing novel sublingual drug-delivery formulations for known active ingredients. The company's lead product is a high-dose sublingual aspirin for acute myocardial infarction in clinical development. Aspire has developed working formulations for melatonin, vitamins, erectile-dysfunction medications, caffeine pre-workout supplements, and other drugs using its patent-pending sublingual absorption technology. The company contracts with third-party manufacturers for production and intends to commercialize products in the United States through its own focused sales force or via licensing arrangements to third parties.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net revenue | 6,202 | — | — | — | — | |
| Cost of revenue | 6,318 | — | — | — | — | |
| Gross margin | −116 | — | — | — | — | |
| General and administrative (including stock-based compensation of $14.1 million and $0, respectively) | 18 | 940,421 | 1 | 976,345 | 25,475 | |
| Research and development | 923,914 | 144,356 | — | — | — | |
| Sales and marketing | 789,829 | 126,094 | — | — | — | |
| Total operating expenses | 19 | 1 | −1 | −976,345 | −25,475 | |
| Loss from operations | −19 | −1 | — | — | — | |
| Interest expense | −9 | −97,988 | — | — | — | |
| Change in fair value of liabilities | 4 | — | — | — | — | |
| Initial recognition of forward purchase liability | −95,062 | — | — | — | — | |
| Loss on extinguishment of debt | −364,109 | — | — | — | — | |
| Total other expense, net | −5 | −97,988 | 6 | 4 | — | |
| Loss before provision for income taxes | −24 | −1 | — | — | — | |
| Income tax expense | — | −1,013 | — | — | — | |
| Net loss | −24 | −1 | 4 | 3 | −25,475 | |
| Weighted average shares outstanding of Common Stock, basic | 1 | 689,913 | — | — | — | |
| Weighted average shares outstanding of Common Stock, diluted | 1 | 689,913 | — | — | — | |
| Earnings Per Share, Diluted | −16.38 | −1.9 | — | — | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-02-28 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash | 1 | — | 3,633 | — | 497,259 | |
| Prepaid expenses and other current assets | 55,102 | — | 144,356 | 81,223 | 600,493 | |
| Inventories | 253,160 | — | — | — | — | |
| Total current assets | 1 | — | 147,989 | 81,223 | 1 | |
| TOTAL ASSETS | 1 | — | 147,989 | 20 | 300 | |
| Accounts payable | 1 | — | 310,219 | — | — | |
| Accrued expenses | 1 | — | — | — | — | |
| Other current liabilities | — | 353,679 | 111,026 | 238,939 | 122,689 | |
| Derivative liability | 40,954 | — | — | — | — | |
| Subscription agreement loans | 2 | — | — | — | — | |
| Convertible note | 1 | — | — | — | — | |
| Total current liabilities | 8 | — | 2 | 403,328 | 303,323 | |
| Forward purchase agreement liability | 95,662 | — | — | — | — | |
| TOTAL LIABILITIES | 8 | — | 2 | 403,328 | 11 | |
| COMMITMENTS AND CONTINGENCIES (Note 9) | — | — | — | — | — | |
| Preferred Stock; $0.0001 par value, 10,000,000 shares authorized, none issued or outstanding | — | — | — | — | — | |
| Common stock; $0.0001 par value; 490,000,000 shares authorized; 3,533,408 and 690,044 issued and outstanding at December 31, 2025 and 2024, respectively | 353 | — | 69 | — | — | |
| Additional paid-in capital | 21 | — | 1 | 11 | — | |
| Accumulated deficit | −27 | — | −3 | −11 | −10 | |
| TOTAL STOCKHOLDERS DEFICIT | −6 | — | −2 | −487,861 | −10 | |
| TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT | 1 | — | 147,989 | 20 | 300 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Amortization of debt discount | 8 | — | — | — | — | |
| Initial recognition of forward purchase agreement liability | 95,062 | — | — | — | — | |
| Issuance of commitment shares under ELOC agreement | 275,000 | — | — | — | — | |
| Stock-based compensation | 14 | — | — | — | — | |
| Prepaid expenses and other current assets | 174,254 | −109,356 | — | — | — | |
| Inventories | −253,160 | — | — | — | — | |
| Accounts payable | −323,776 | 247,846 | — | — | — | |
| Accrued expenses | 1 | — | — | — | — | |
| Due to related party | — | 906,196 | — | — | — | |
| Other current liabilities | −111,026 | — | — | — | — | |
| NET CASH FLOWS USED IN OPERATING ACTIVITIES | −5 | −265,186 | −653,107 | −1 | −238,596 | |
| Issuance of common stock | — | 257,645 | — | — | — | |
| Proceeds from recapitalization | 265,827 | — | — | — | — | |
| Proceeds from issuance of convertible notes | 10 | — | — | — | — | |
| Repayment of convertible notes | −3 | — | — | — | — | |
| Transaction costs paid in connection with convertible notes | −907,499 | — | — | — | — | |
| Proceeds from notes payable - related party | 50,000 | — | — | — | — | |
| Repayment of notes payable related party | −701,924 | — | — | — | — | |
| NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES | 6 | 257,645 | −285 | 297 | 238,596 | |
| NET CHANGE IN CASH | 1 | −7,541 | −497,259 | 497,259 | — | |
| Accounts payable and other liabilities combined, net | 5 | — | — | — | — | |
| Shares issued pursuant to settlement agreement | 317,250 | — | — | — | — | |
| Issuance of shares in reverse recapitalization | 5 | — | — | — | — | |
| Conversion of warrants | 14 | — | — | — | — | |
| Conversion of convertible notes | 10 | — | — | — | — | |
| Issuance of shares under working capital loans and non redemption agreements | 14 | — | — | — | — | |
| Cash paid for interest | 44,388 | — | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Aspire Biopharma Holdings, Inc.'s CIK number?
Aspire Biopharma Holdings, Inc.'s SEC CIK number is 0001847345 (1847345). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Aspire Biopharma Holdings, Inc.'s SEC filings?
All of Aspire Biopharma Holdings, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.